



JPW

Mail Stop Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


CERTIFICATE OF MAILING BY "FIRST-CLASS-MAIL"

Attorney Docket No. : 202.14
Applicant(s) : Christopher L. Reading, et al
Application S/N : 10/728,400
For : Therapeutic Treatment Methods 2
Attorney : Daryl D. Muenchau, Registration No. 36,616
Date of Deposit : May 14, 2004

I hereby certify that the accompanying:

Transmittal; Information Disclosure Statement by Applicant (Form PTO-1449)
and 55 references; and Return Postage Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail Post Office to Addressee" service under 37 CFR 1.8 on the date indicated above and are addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Brenda Mannon-Freeman



Serial No. 10/728,400

Filing Date: December 05, 2003

Inventor(s): Christopher L. Reading, et al

PATENT

Attorney Docket No. 202.14

Page 1

MAIL STOP AMENDMENTS
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL


Dear Sir:

Enclosed are:

- (X) Form PTO-1449 listing 55 references. This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b)(3).
- (X) First Class Mailing Certificate (37 C.F.R. § 1.8).
- (X) Return postage prepaid postcard.
- (X) The Commissioner is hereby authorized to charge any fees which may be required, now or in the future, or credit any overpayment to **Deposit Account No. 501536**.
- (X) Please use **Customer No. 26,551** for the correspondence address.

Daryl D. Muenchau
Registration No. 36,616
Attorney of Record

Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Phone: 858-587-9333
Customer No. 26,551



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.14APPLICATION NO.
10/728,400INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Reading, et al.FILING DATE
12/05/03GROUP
1614

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	3,080,360	03/05/63	Pappo			
	3,137,710	06/16/64	de Ruggieri, et al			
	3,153,063	10/13/64	de Ruggieri, et al			
	3,155,690	11/03/64	Cole			
	3,264,326	08/02/66	Clark, et al			
	3,631,033	12/28/71	Nathansohn, et al			
	4,412,953	11/01/83	Winters			
	4,898,694	02/06/90	Schwartz, et al			
	5,077,284	12/31/91	Loria, et al			
	5,206,008	04/27/93	Loria			
	5,277,907	01/11/94	Loria			
	5,387,583	02/07/95	Loria			
	5,461,042	10/24/95	Loria			
	5,478,566	12/26/95	Loria			
	5,585,371	12/17/96	Lardy			
	5,635,496	06/03/97	Daynes, et al			
	5,641,766	06/24/97	Loria			
	5,641,768	06/24/97	Lardy			
	5,686,438	11/11/97	Daynes, et al			
	5,707,983	01/13/98	Lardy			
	5,811,418	09/22/98	Daynes, et al			
	5,827,841	10/27/98	Daynes, et al			
	5,885,977	03/23/99	Pauza, et al			
	5,977,095	11/02/99	Araneo, et al			
	6,187,767 B1	02/13/01	Araneo, et al			
	6,432,940	08/13/02	Labrie			

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
	APPLICANT Reading, et al.	
	FILING DATE 12/05/03	GROUP 1614

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

EXAMINER INITIAL	DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	2003-0060425 A1	Ahlem, et al			
	2003-0083231 A1	Ahlem, et al			
	2004-0043973 A1	Ahlem, et al			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Arth, G., et al., "Steroidal androgen biosynthesis inhibitors", <i>J. Med. Chem.</i> , Vol. 14(8), pp. 675-79, (1971).
	Belovsky, O., et al., "Inhibition of glucose-6-phosphate dehydrogenase by steroids -VIII: Effects of synthetic C ₁₉ and C ₂₀ steroids upon placental glucose-6-phosphate dehydrogenase", <i>J. of Steroid Biochemistry</i> , Vol. 5, pp. 697-700, (1974).
	Chavis, C., et al., "New steroidal nitrosoureas", <i>Steroids</i> , Vol. 39 (2), pp. 129-47, (1982).
	Chavis, C., et al., "N.M>R. studies of D-Ribosylamines in solution: Derivatives of primary amines", <i>Carbohydrate Research</i> , 113, pp. 1-20, (1983).
	Davis, M., et al, "Steroid Amines. Part II. 17 α -aminoandrostane derivatives", <i>J. Chem. Soc.</i> , pp. 1698-1700, (1966).
	Flouret, G., et al., "17-aminocylamido-5-androsten-3 β -ols", <i>J. Med Chem</i> , Vol. 11, pp. 880-82(1968).
	Hewett, C., et al., "Amino-steroids. Part IV. 16 β -morpholino-17-oxo- and 17 β -morpholino-16-oxo-5 α -androstanes", <i>J. Chem. Soc.</i> , pp. 1880-83, (1969)
	Hussain, A., et al, "Testosterone 17 β -N, N-dimethylglycinate hydrochloride: A prodrug with a potential for nasal delivery of testosterone", <i>J. Pharmaceutical Sciences</i> , Vol. 91, pp. 785-89, (2002).
	Irmscher, K., et al., "Cholesterol analogues with OXA and OXA-AZA side chain a novel class of inhibitors of cholesterol biosynthesis", <i>Steroids</i> , Vol. 7(6), pp. 557-76, (1966).
	Johnson, K., et al., "Solution kinetics of a water soluble hydrocortisone prodrug: Hydrocortisone-21-lysinate", <i>J. of Pharmaceutical Sciences</i> , Vol 74(1), pp. 87-89, (1985).
	Jones, J., et al., "Steroids and steroidases. 10. Studies on some potentially antitumor active androstane compounds containing C-17 nitrogen mustard function", <i>J. of Med. Chem.</i> , Vol 14 (9), pp. 827-33, (1971).
	Kabara, J., et al, "Structure-function activity of azasterols and nitrogen-containing steroids", <i>Lipids</i> , Vol. 11(10), pp. 755-62, (1976).
	Kuehne, M., et al, "Steroidal dihydro-1,3-oxazines as antitumor agents", <i>J. Med. Pharm. Chem.</i> , 5, pp. 281-96, (1962)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
	APPLICANT Reading, et al.	
	FILING DATE 12/05/03	GROUP 1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Lu, M., et al., "Inhibition of cholesterol side-chain cleavage. 4. Synthesis of A or B ring modified azacholesterols", <i>J. Med. Chem.</i> , 24, pp. 1038-42, (1981).
	Machkova, Z., et al., "Preparation of some amidic 6-ketosteroids as potential inhibitors of postecdysial cuticle sclerotization in <i>pyrrhocoris apertus</i> L", <i>Collect Czech Chem Commun</i> , Vol 39, pp 1091-97, (1974)
	Mahler, H., et al., "Nucleic acid interactions. VI. Effects of steroidal diamines", <i>Nucleic Acid Interactions</i> , Vol. 5 (7), pp. 2177-91, (1966).
	Matoba, K., et al., "Syntheses of Vitamin D analogues I", <i>Chem. Phar. Bull.</i> , (30 (12, pp. 4596-96, (1982).
	Mokotoff, M., et al, "Peptidyl aminosteroids as potential new antiarrhythmic agents", <i>Steroids</i> , Vol. 55, pp. 399-404, (1990).
	Pettit, G., et al., "Structural biochemistry. IV. 3 β -hydroxy-17 β -(L-prolyl) amino-androst-5-ene ¹⁻³ⁿ ", <i>Canadian J. of Chem.</i> , Vol 45, pp502-07, (1967).
	Robinson, C., et al., "The synthesis of 17 α -amino-5-androsten-3 β -ol; N.M.R. spectra of 17-substituted androstanes", <i>Steroids</i> , 6(5), pp.509-18, (1965).
	Schreck, R., et al, "Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1" <i>Embo J</i> , 10, pp. 2247-58, (1991).
	Singh, H., et al., "Steroids & related studies: Part 82 – chandonium related azasteroidal neuromuscular blockers", <i>Indian J. of chem.</i> , Vol. 27B, pp. 508-12, (1988).
	Vincze, I., et al, "Steroids 54: Amino acylamidosteroids", <i>Steroids</i> , 61, pp. 697-702, (1996).
	Wheeler, O., et al., "Steroid derivatives of cysteamine and cysteine", <i>Canadian J. of Chem.</i> , Vol 47, pp. 160-62, (1969).
	Whitnall, M., et al, "Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice", <i>Intl. J. or Immunopharmacology</i> , 22, pp. 1 – 14, (2000).
	Zheng, G, et al., "Tricarbocyanine cholesteryl laureates labeled LDL: New near infrared fluorescent probes (NIRFs) for monitoring tumors and gene therapy of familial hypercholesterolemia", <i>Bioorganic & Med Chem Letters</i> , 12, pp. 1485-88, (2002).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	